Cara Therapeutics May Be 1 Clinical Trial Away From a $1 Billion Valuation

By: / Ratchanida Thippayos / Standard License

The big question on investors’ minds is what marijuana stock could be the next to move higher? While there’s no way of knowing with any certainty, one of the industry’s worst-performing stocks of late could actually turn out to be one of its best performers in the months to come. If just a single clinical trial works in favor of Cara Therapeutics (NASDAQ:CARA), it could regain everything it’s recently lost and possibly hit a $1 billion market cap.

View Original Article Here

Repost is the designation for articles collected from the Internet whose content may interest our readers. These articles are not written by our staff and they do not necessarily reflect our views.

Related posts